FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Royalty Pharma plc Stock AnalysisComprehensive stock analysis for Royalty Pharma plc (RPRX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRPRX
RPRX
Royalty Pharma plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RPRX
Home🔹Stocks🔹Royalty Pharma plc

Royalty Pharma plc

RPRX•NASDAQ

Royalty Pharma plc

RPRX•NASDAQ
Market cap
$25.79B
Sentiment

Your view on RPRX

Mkt Cap
$25.79B
Sentiment
Your view
RPRX
Royalty Pharma plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RPRX
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Royalty Pharma plc

Industry
Biotechnology
Sector
Healthcare
CEO
Pablo Gerardo Legorreta
Headquarters
110 East 59th Street, New York City, NY, US
Industry
Biotechnology
Sector
Healthcare
CEO
Pablo Gerardo Legorreta
Headquarters
110 East 59th Street, New York City, NY, US
Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News